Zoetis Inc Intrinsic Value Calculator – Zoetis Rushing to Create Vaccine for Avian Flu as Outbreak Grows

Trending News 🌧️

Zoetis Inc ($NYSE:ZTS), which is a leading animal health company, is rushing to create an effective vaccine for avian flu as the outbreak of the virus continues to increase. Bloomberg recently reported that Zoetis has been using its industry connections and resources to create a vaccine to tackle this growing pandemic. The company has been utilizing their expansive research and development capabilities to create a safety measure that could protect the world from this virus. Zoetis has a long history of providing excellent animal care solutions to their customers worldwide. Their aim is to create innovative solutions in the animal health industry that enables them to provide high-quality products and services. They are passionate about helping animals and their health, so it comes as no surprise that they are also taking steps to create a vaccine for avian flu.

This is yet another example of their commitment to creating products that benefit the world. The growing outbreak of avian flu has caused a great deal of concern among animal health professionals and those who have close contact with birds. As a result, Zoetis is doing its part to try to prevent the spread of the virus with their vaccine production. If successful, it could be a major breakthrough in the fight against avian flu and save countless lives. Zoetis is doing its part in the battle against this virus and hopefully their efforts will pay off.

Market Price

On Wednesday, the company’s stock opened at $167.0 and closed at $167.6, a 0.3% increase from its prior closing price of $167.1. This is indicative of the market’s confidence in ZOETIS’ ability to develop an effective vaccine to manage the current Avian Flu crisis. While treatments already exist, the urgency of the situation has caused the company to direct its resources towards combating this global health issue. They are now racing to create an effective vaccine and safeguard the health of people and their poultry. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Zoetis Inc. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Zoetis Inc. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Zoetis Inc. More…

Key Ratios Snapshot

Some of the financial key ratios for Zoetis Inc are shown below. More…

Analysis – Zoetis Inc Intrinsic Value Calculator

At GoodWhale, we have conducted an analysis of ZOETIS INC‘s wellbeing and have come to the conclusion that the fair value of their shares is around $189.0, calculated using our proprietary Valuation Line. This implies that the ZOETIS INC stock is currently being traded at $167.6, which is a fair price that is slightly undervalued by 11.3%. Therefore, this presents a possible buying opportunity for those who are looking for potential investments in the stock market. We believe that this is a viable option for those who are looking to capitalize on the current market conditions. More…

Peers

Zoetis Inc. is a global animal health company that develops, manufactures, and markets a wide range of veterinary products. The company’s products include vaccines, parasiticides, pharmaceuticals, diagnostics, and biologics. Zoetis Inc. has a broad portfolio of products that are used in the prevention, treatment, and control of disease in animals. The company’s competitors include BioGaia AB, Krka d.d., and Phibro Animal Health Corp.

– BioGaia AB ($OTCPK:BIOGY)

Biogaia is a Swedish biotech company that markets probiotic products for infants, children, and adults. The company’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.

Biogaia’s market cap is 800.05M as of 2022. The company has a Return on Equity of 10.86%. Biogaia’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.

– Krka d.d. ($LTS:0HLK)

Krka d.d. is a Slovenian pharmaceutical company. It is the largest pharmaceutical company in Slovenia and one of the largest in the Balkans. The company was founded in 1959 and is headquartered in Novo mesto. Krka d.d. has a market cap of 2.77B as of 2022 and a Return on Equity of 12.85%. The company’s main products are prescription drugs, over-the-counter drugs, and medical devices.

– Phibro Animal Health Corp ($NASDAQ:PAHC)

Phibro Animal Health Corporation is a diversified animal health and specialty ingredients company with products in over 100 countries. The company’s products are sold through veterinarians, distributors, and feed stores. Phibro Animal Health Corporation’s mission is to improve the health and productivity of animals. The company’s products are used in a variety of animals, including cattle, swine, poultry, and aquaculture. Phibro Animal Health Corporation’s products are designed to improve the health and productivity of animals while providing a safe and healthy environment for them to live in.

Summary

Zoetis Inc. is an animal health company that is currently developing a vaccine to combat the spread of bird flu. It provides products and services that are tailored to meet the needs of veterinary professionals, livestock producers and pet owners. It continues to invest in research and development initiatives to develop innovative new products, and its portfolio consists of a wide range of animal vaccines, pharmaceuticals, and other products. Investors should consider Zoetis Inc. as a potential opportunity for long-term growth, as the company’s strong financials and expanding product offerings have the potential to deliver strong returns.